Regulation of impaired angiogenesis in diabetic dermal wound healing by microRNA-26a

Basak Icli, Christoph S. Nabzdyk, Jorge Lujan-Hernandez, Meghan Cahill, Michael E. Auster, A. K.M. Wara, Xinghui Sun, Denizhan Ozdemir, Giorgio Giatsidis, Dennis P. Orgill, Mark W. Feinberg

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Wound healing is a physiological reparative response to injury and a well-orchestrated process that involves hemostasis, cellular migration, proliferation, angiogenesis, extracellular matrix deposition, and wound contraction and re-epithelialization. However, patients with type 2 diabetes mellitus (T2D) are frequently afflicted with impaired wound healing that progresses into chronic wounds or diabetic ulcers, and may lead to complications including limb amputation. Herein, we investigate the potential role of microRNA-26a (miR-26a) in a diabetic model of wound healing. Expression of miR-26a is rapidly induced in response to high glucose in endothelial cells (ECs). Punch skin biopsy wounding of db/db mice revealed increased expression of miR-26a (~. 3.5-fold) four days post-wounding compared to that of WT mice. Local administration of a miR-26a inhibitor, LNA-anti-miR-26a, induced angiogenesis (up to ~. 80%), increased granulation tissue thickness (by 2.5-fold) and accelerated wound closure (53% after nine days) compared to scrambled anti-miR controls in db/db mice. These effects were independent of altered M1/M2 macrophage ratios. Mechanistically, inhibition of miR-26a increased its target gene SMAD1 in ECs nine days post-wounding of diabetic mice. In addition, high glucose reduced activity of the SMAD1-3'-UTR. Diabetic dermal wounds treated with LNA-anti-miR-26a had increased expression of ID1, a downstream modulator or SMAD1, and decreased expression of the cell cycle inhibitor p27. These findings establish miR-26a as an important regulator on the progression of skin wounds of diabetic mice by specifically regulating the angiogenic response after injury, and demonstrate that neutralization of miR-26a may serve as a novel approach for therapy.

Original languageEnglish (US)
Pages (from-to)151-159
Number of pages9
JournalJournal of Molecular and Cellular Cardiology
Volume91
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Fingerprint

MicroRNAs
Wound Healing
Skin
Wounds and Injuries
Endothelial Cells
Re-Epithelialization
Glucose
Granulation Tissue
3' Untranslated Regions
Hemostasis
Amputation
Type 2 Diabetes Mellitus
Ulcer
Extracellular Matrix
Cell Cycle
Extremities
Macrophages
Cell Proliferation
Biopsy
Genes

Keywords

  • Angiogenesis
  • Diabetes
  • MicroRNA
  • Wound healing

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

Icli, B., Nabzdyk, C. S., Lujan-Hernandez, J., Cahill, M., Auster, M. E., Wara, A. K. M., ... Feinberg, M. W. (2016). Regulation of impaired angiogenesis in diabetic dermal wound healing by microRNA-26a. Journal of Molecular and Cellular Cardiology, 91, 151-159. https://doi.org/10.1016/j.yjmcc.2016.01.007

Regulation of impaired angiogenesis in diabetic dermal wound healing by microRNA-26a. / Icli, Basak; Nabzdyk, Christoph S.; Lujan-Hernandez, Jorge; Cahill, Meghan; Auster, Michael E.; Wara, A. K.M.; Sun, Xinghui; Ozdemir, Denizhan; Giatsidis, Giorgio; Orgill, Dennis P.; Feinberg, Mark W.

In: Journal of Molecular and Cellular Cardiology, Vol. 91, 01.02.2016, p. 151-159.

Research output: Contribution to journalArticle

Icli, B, Nabzdyk, CS, Lujan-Hernandez, J, Cahill, M, Auster, ME, Wara, AKM, Sun, X, Ozdemir, D, Giatsidis, G, Orgill, DP & Feinberg, MW 2016, 'Regulation of impaired angiogenesis in diabetic dermal wound healing by microRNA-26a', Journal of Molecular and Cellular Cardiology, vol. 91, pp. 151-159. https://doi.org/10.1016/j.yjmcc.2016.01.007
Icli, Basak ; Nabzdyk, Christoph S. ; Lujan-Hernandez, Jorge ; Cahill, Meghan ; Auster, Michael E. ; Wara, A. K.M. ; Sun, Xinghui ; Ozdemir, Denizhan ; Giatsidis, Giorgio ; Orgill, Dennis P. ; Feinberg, Mark W. / Regulation of impaired angiogenesis in diabetic dermal wound healing by microRNA-26a. In: Journal of Molecular and Cellular Cardiology. 2016 ; Vol. 91. pp. 151-159.
@article{013dc3670c5642ba9059cdbbc85c556d,
title = "Regulation of impaired angiogenesis in diabetic dermal wound healing by microRNA-26a",
abstract = "Wound healing is a physiological reparative response to injury and a well-orchestrated process that involves hemostasis, cellular migration, proliferation, angiogenesis, extracellular matrix deposition, and wound contraction and re-epithelialization. However, patients with type 2 diabetes mellitus (T2D) are frequently afflicted with impaired wound healing that progresses into chronic wounds or diabetic ulcers, and may lead to complications including limb amputation. Herein, we investigate the potential role of microRNA-26a (miR-26a) in a diabetic model of wound healing. Expression of miR-26a is rapidly induced in response to high glucose in endothelial cells (ECs). Punch skin biopsy wounding of db/db mice revealed increased expression of miR-26a (~. 3.5-fold) four days post-wounding compared to that of WT mice. Local administration of a miR-26a inhibitor, LNA-anti-miR-26a, induced angiogenesis (up to ~. 80{\%}), increased granulation tissue thickness (by 2.5-fold) and accelerated wound closure (53{\%} after nine days) compared to scrambled anti-miR controls in db/db mice. These effects were independent of altered M1/M2 macrophage ratios. Mechanistically, inhibition of miR-26a increased its target gene SMAD1 in ECs nine days post-wounding of diabetic mice. In addition, high glucose reduced activity of the SMAD1-3'-UTR. Diabetic dermal wounds treated with LNA-anti-miR-26a had increased expression of ID1, a downstream modulator or SMAD1, and decreased expression of the cell cycle inhibitor p27. These findings establish miR-26a as an important regulator on the progression of skin wounds of diabetic mice by specifically regulating the angiogenic response after injury, and demonstrate that neutralization of miR-26a may serve as a novel approach for therapy.",
keywords = "Angiogenesis, Diabetes, MicroRNA, Wound healing",
author = "Basak Icli and Nabzdyk, {Christoph S.} and Jorge Lujan-Hernandez and Meghan Cahill and Auster, {Michael E.} and Wara, {A. K.M.} and Xinghui Sun and Denizhan Ozdemir and Giorgio Giatsidis and Orgill, {Dennis P.} and Feinberg, {Mark W.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.yjmcc.2016.01.007",
language = "English (US)",
volume = "91",
pages = "151--159",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Regulation of impaired angiogenesis in diabetic dermal wound healing by microRNA-26a

AU - Icli, Basak

AU - Nabzdyk, Christoph S.

AU - Lujan-Hernandez, Jorge

AU - Cahill, Meghan

AU - Auster, Michael E.

AU - Wara, A. K.M.

AU - Sun, Xinghui

AU - Ozdemir, Denizhan

AU - Giatsidis, Giorgio

AU - Orgill, Dennis P.

AU - Feinberg, Mark W.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Wound healing is a physiological reparative response to injury and a well-orchestrated process that involves hemostasis, cellular migration, proliferation, angiogenesis, extracellular matrix deposition, and wound contraction and re-epithelialization. However, patients with type 2 diabetes mellitus (T2D) are frequently afflicted with impaired wound healing that progresses into chronic wounds or diabetic ulcers, and may lead to complications including limb amputation. Herein, we investigate the potential role of microRNA-26a (miR-26a) in a diabetic model of wound healing. Expression of miR-26a is rapidly induced in response to high glucose in endothelial cells (ECs). Punch skin biopsy wounding of db/db mice revealed increased expression of miR-26a (~. 3.5-fold) four days post-wounding compared to that of WT mice. Local administration of a miR-26a inhibitor, LNA-anti-miR-26a, induced angiogenesis (up to ~. 80%), increased granulation tissue thickness (by 2.5-fold) and accelerated wound closure (53% after nine days) compared to scrambled anti-miR controls in db/db mice. These effects were independent of altered M1/M2 macrophage ratios. Mechanistically, inhibition of miR-26a increased its target gene SMAD1 in ECs nine days post-wounding of diabetic mice. In addition, high glucose reduced activity of the SMAD1-3'-UTR. Diabetic dermal wounds treated with LNA-anti-miR-26a had increased expression of ID1, a downstream modulator or SMAD1, and decreased expression of the cell cycle inhibitor p27. These findings establish miR-26a as an important regulator on the progression of skin wounds of diabetic mice by specifically regulating the angiogenic response after injury, and demonstrate that neutralization of miR-26a may serve as a novel approach for therapy.

AB - Wound healing is a physiological reparative response to injury and a well-orchestrated process that involves hemostasis, cellular migration, proliferation, angiogenesis, extracellular matrix deposition, and wound contraction and re-epithelialization. However, patients with type 2 diabetes mellitus (T2D) are frequently afflicted with impaired wound healing that progresses into chronic wounds or diabetic ulcers, and may lead to complications including limb amputation. Herein, we investigate the potential role of microRNA-26a (miR-26a) in a diabetic model of wound healing. Expression of miR-26a is rapidly induced in response to high glucose in endothelial cells (ECs). Punch skin biopsy wounding of db/db mice revealed increased expression of miR-26a (~. 3.5-fold) four days post-wounding compared to that of WT mice. Local administration of a miR-26a inhibitor, LNA-anti-miR-26a, induced angiogenesis (up to ~. 80%), increased granulation tissue thickness (by 2.5-fold) and accelerated wound closure (53% after nine days) compared to scrambled anti-miR controls in db/db mice. These effects were independent of altered M1/M2 macrophage ratios. Mechanistically, inhibition of miR-26a increased its target gene SMAD1 in ECs nine days post-wounding of diabetic mice. In addition, high glucose reduced activity of the SMAD1-3'-UTR. Diabetic dermal wounds treated with LNA-anti-miR-26a had increased expression of ID1, a downstream modulator or SMAD1, and decreased expression of the cell cycle inhibitor p27. These findings establish miR-26a as an important regulator on the progression of skin wounds of diabetic mice by specifically regulating the angiogenic response after injury, and demonstrate that neutralization of miR-26a may serve as a novel approach for therapy.

KW - Angiogenesis

KW - Diabetes

KW - MicroRNA

KW - Wound healing

UR - http://www.scopus.com/inward/record.url?scp=84954284990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954284990&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2016.01.007

DO - 10.1016/j.yjmcc.2016.01.007

M3 - Article

VL - 91

SP - 151

EP - 159

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

ER -